Nanocytological Field Carcinogenesis Detection to Mitigate Overdiagnosis of Prostate Cancer: A Proof of Concept Study

Purpose To determine whether nano-architectural interrogation of prostate field carcinogenesis can be used to predict prognosis in patients with early stage (Gleason 6) prostate cancer (PCa), which is mostly indolent but frequently unnecessarily treated. Materials and Methods We previously developed partial wave spectroscopic microscopy (PWS) that enables quantification of the nanoscale intracellular architecture (20–200nm length scale) with remarkable accuracy. We adapted this technique to assess prostate needle core biopsies in a case control study from men with Gleason 6 disease who either progressed (n = 20) or remained indolent (n = 18) over a ~3 year follow up. We measured the parameter disorder strength (Ld) characterizing the spatial heterogeneity of the nanoscale cellular structure and nuclear morphology from the microscopically normal mucosa ~150 histologically normal epithelial cells. Results There was a profound increase in nano-architectural disorder between progressors and non-progressors. Indeed, the Ld from future progressors was dramatically increased when compared to future non-progressors (1±0.065 versus 1.30±0.0614, respectively p = 0.002). The area under the receiver operator characteristic curve (AUC) was 0.79, yielding a sensitivity of 88% and specificity of 72% for discriminating between progressors and non-progressors. This was not confounded by demographic factors (age, smoking status, race, obesity), thus supporting the robustness of the approach. Conclusions We demonstrate, for the first time, that nano-architectural alterations occur in prostate cancer field carcinogenesis and can be exploited to predict prognosis of early stage PCa. This approach has promise in addressing the clinically vexing dilemma of management of Gleason 6 PCa and may provide a paradigm for dealing with the larger issue of cancer overdiagnosis.

[1]  D. Moreira,et al.  Smoking and prostate cancer survival and recurrence. , 2011, Asian journal of andrology.

[2]  Vadim Backman,et al.  Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. , 2010, Cancer research.

[3]  P. Corso,et al.  National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men With Localized Prostate Cancer , 2012, Annals of Internal Medicine.

[4]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[5]  D. Moore,et al.  Alteration of Gene Expression in Normal-Appearing Colon Mucosa of APCmin Mice and Human Cancer Patients , 2004, Cancer Research.

[6]  P. Carroll,et al.  The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. , 2007, The Journal of urology.

[7]  Vadim Backman,et al.  Nanocytology of rectal colonocytes to assess risk of colon cancer based on field cancerization. , 2012, Cancer research.

[8]  J. Stanford,et al.  Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle‐aged men , 2007, Cancer.

[9]  H Ballentine Carter,et al.  American Urological Association (AUA) Guideline on prostate cancer detection: process and rationale , 2013, BJU international.

[10]  T. H. van der Kwast,et al.  Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. , 2013, Journal of the National Cancer Institute.

[11]  J. Epstein,et al.  Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. , 2014, The Journal of urology.

[12]  Vadim Backman,et al.  Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening , 2013, Endoscopy.

[13]  Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment , 2014, BMC Cancer.

[14]  M. Cooperberg,et al.  Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. , 2015, European urology.

[15]  J. Rathmell,et al.  Results of the two incidence screenings in the National Lung Screening Trial. , 2013, The New England journal of medicine.

[16]  J. Griffith,et al.  Markers of Field Cancerization: Proposed Clinical Applications in Prostate Biopsies , 2012, Prostate cancer.

[17]  Vadim Backman,et al.  Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. , 2009, Cancer research.

[18]  P. Corso,et al.  National Institutes of Health State-of-the-Science Conference , 2012 .

[19]  V. Backman,et al.  Advances in Biophotonics Detection of Field Carcinogenesis for Colon Cancer Risk Stratification , 2013, Journal of Cancer.

[20]  Allen Taflove,et al.  Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells , 2008, Proceedings of the National Academy of Sciences.

[21]  F. Guimont,et al.  Mitochondria, prostate cancer, and biopsy sampling error. , 2013, Discovery medicine.

[22]  Vadim Backman,et al.  Role of cytoskeleton in controlling the disorder strength of cellular nanoscale architecture. , 2010, Biophysical journal.

[23]  Brian Reid,et al.  Overdiagnosis and overtreatment in cancer: an opportunity for improvement. , 2013, JAMA.

[24]  T. Gomes,et al.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. , 2012 .

[25]  D. Chan,et al.  Biomarkers in prostate cancer: what's new? , 2014, Current opinion in oncology.

[26]  Stacey A. Kenfield,et al.  Smoking and prostate cancer survival and recurrence. , 2011, JAMA.

[27]  Andrew H. Beck,et al.  Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression , 2015, Modern Pathology.

[28]  Vadim Backman,et al.  Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells , 2013, International journal of cancer.

[29]  George Vasmatzis,et al.  Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer. , 2012, The American journal of pathology.

[30]  P. Carroll,et al.  A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. , 2014, Urology.

[31]  J. Patard,et al.  Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. , 2009, European urology.

[32]  Theodore L DeWeese,et al.  Clinical practice. Localized prostate cancer. , 2007, The New England journal of medicine.

[33]  Vadim Backman,et al.  Light-scattering technologies for field carcinogenesis detection: a modality for endoscopic prescreening. , 2011, Gastroenterology.

[34]  W. Zimmer,et al.  New concepts concerning prostate cancer screening , 2014, Experimental biology and medicine.

[35]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[36]  R. Montironi,et al.  Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer , 2000, Virchows Archiv.

[37]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[38]  Avrum Spira,et al.  The Field of Tissue Injury in the Lung and Airway , 2008, Cancer Prevention Research.

[39]  Vijayalakshmi Ananthanarayanan,et al.  Evidence for field cancerization of the prostate , 2009, The Prostate.

[40]  Theodore L. DeWeese,et al.  Localized Prostate Cancer , 2007 .

[41]  G. Tseng,et al.  Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. , 2013, The American journal of pathology.

[42]  G. Dotto Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. , 2014, The Journal of clinical investigation.

[43]  V. Backman,et al.  Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification. , 2011, Future oncology.

[44]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[45]  Andrea Califano,et al.  A Molecular Signature Predictive of Indolent Prostate Cancer , 2013, Science Translational Medicine.